Designing an Appropriate Immunosuppressive Regimen to Minimize Impact of the Immune Response to Administered AAV Therapies

Time: 12:00 pm
day: Day Two


This panel will be a structured conversation designed to answer key questions such as:

  • Discuss the best methods to circumvent the activation of both innate and adaptive immune response to the protein capsid, vector genome and transgene product to ensure no SAEs to reduce risk of clinical holds
  • Explore immunomodulating and suppressive regimens currently used in clinical trials
  • An in-depth look at pre-conditioning the patient prior to AAV administration or post treat the patient in response to the
    activated immune system?